BioMarin Pharmaceutical Inc

BMRN 
(NASDAQ) 
 
$ 103,92 <%= Resources.Global.txtUp %>
Opdateret 17-07-2018
Ændring % 1,16% Stigning i aktiekurs
Ændring 1,19 Stigning i aktiekurs
Volume 347.370
Høj $ 104,42
Lav $ 102,26
Åben $ 102,26
ISIN
Seneste luk $ 102,73
# af aktier 176,71M
Markedsværdi 18.364M USD
I dag

Market closed
BioMarin Pharmaceutical Inc
Markedet er lukket, åbner klokken 15:30
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  103,92 3,8% Stigning i aktiekurs 8,7% Stigning i aktiekurs 23,1% Stigning i aktiekurs 15,7% Stigning i aktiekurs 19,9% Stigning i aktiekurs
Powered by TradingView

Firmaprofil

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to longstanding U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2018 03:17:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB3 - 2018-07-18 03:17:50 - 2018-07-18 03:17:50 - 1 - Website: OKAY